Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217 by Branislav Kovacech, Nicholas C. Cullen, Petr Novak, Jozef Hanes, Eva Kontsekova, Stanislav Katina, Vojtech Parrak, Michal Fresser, Jeroen Vanbrabant, Howard H. Feldman, Bengt Winblad, Erik Stoops, Eugeen Vanmechelen, Norbert Zilka

Get full text